Data from population-based real-world cohorts, such as the Dutch Melanoma Treatment Registry (DMTR)., could be used to directly compare the effectiveness of adjuvant BRAF/MEK-inhibition to that of adjuvant anti-PD-1 treatment in daily practice. This evidence concerns the gene BRAF and melanoma.